Randomized trials have unanimously shown the benefits of oral antibiotic treatments for stable patients with bacteremia (1). However, transition to oral therapy has been usually performed after several days of intravenous treatment—frequently up to 7 days (2)—highlighting the need for evidence of the safety of earlier oral treatments (3).

Antimicrobial resistance can decline due to compensatory mutations or genetic reversions to wild-type alleles. Here, the authors analyse the decline of ciprofloxacin resistance in nfxB-defective Pseud...